LegoChem signed a technology transfer agreement with the CEVI (new virus) Convergence Research Group involving eight government-funded research institutes led by the Korea Research Institute of Chemical Technology that has studied new virus diagnosis, vaccine development, treatment technologies.
Originally, the group has developed a candidate substance for the treatment of MERS, but animal testing showed it was 50 times more effective than remdesivir developed by Gilead Sciences and introduced the treatment of serious COVID-19 patients in South Korea.
"It is considered highly likely to be developed as a new drug due to its very good substance and low toxicity," CEVI Convergence Research Group head Kim Beom-tae said. LegoChem was optimistic saying it would quickly enter clinical trials to develop treatments that work for mutating viruses.
The research group transferred a synthetic antigen vaccine candidate with high ability to produce neutralizing antibodies to HK inno.N.
South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year. Researchers have been involved in quick experiments to check the efficacy of various drugs. For a short-term task, GC Pharma, a biotech company, has been involved in the development of GC5131A, an immunoglobulin drug based on plasma containing antibodies.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.